Lincoln Pharmaceuticals Share Price

Pursuant to provision of Regulation 74(5) of SEBI (Depository and Participants) Regulation, 2018, we hereby submit the confirmation certificate received from MUFG Intime India Private Limited, Registrar and Share Transfer Agent (RTA) for the Quarter ended June 30, 2026.

• BSE India
• 2 weeks 3 days ago

Intimation of Trading Window Closure for the Quarter ended June 30, 2026.

• BSE India
• 4 weeks 1 day ago

<h3><span style="font-size:16px;"><strong>Pharmaceuticals company Lincoln Pharmaceuticals announced Q4FY26 & FY26 results</strong></span></h3> <p><strong _ngcontent-ng-c3779765592="">Consolidated Financial Highlights:</strong></p> <ul> <li _ngcontent-ng-c3779765592="">Consolidated total income for Q4FY26 was Rs. 18,308.00 lakh, representing a YoY growth of 13.50% compared to Rs. 16,130.00 lakh in Q4FY25.</li> <li _ngcontent-ng-c3779765592="">Consolidated EBITDA for Q4FY26 stood at Rs. 2,066.00 lakh, up 4.13% YoY from Rs. 1,984.00 lakh.</li> <li _ngcontent-ng-c3779765592="">Consolidated net profit for Q4FY26 was Rs. 1,163.00 lakh, showing a YoY growth of 0.52% from Rs. 1,157.00 lakh.</li> <li _ngcontent-ng-c3779765592="">For the full year FY26, consolidated total income reached Rs. 70,448.00 lakh, a growth of 9.10% YoY compared to Rs. 64,571.00 lakh in FY25.</li> <li _ngcontent-ng-c3779765592="">Consolidated EBITDA for FY26 was reported at Rs. 13,114.00 lakh, growing 5.78% YoY from Rs. 12,397.00 lakh in FY25.</li> <li _ngcontent-ng-c3779765592="">Consolidated net profit for the full year FY26 reached Rs. 8,789.00 lakh, an increase of 6.74% over Rs. 8,235.00 lakh in FY25.</li> <li _ngcontent-ng-c3779765592="">Consolidated EPS for FY26 was reported at Rs. 43.88 per share.</li> </ul> <p><strong _ngcontent-ng-c3779765592="">Standalone Financial Highlights: </strong></p> <ul> <li _ngcontent-ng-c3779765592="">Revenue from operations for Q4FY26 stood at Rs. 18,727.73 lakh, representing a YoY increase of 11.35% compared to Rs. 16,818.31 lakh in Q4FY25 and a QoQ increase of 12.60% from Rs. 16,632.20 lakh in Q3FY26.</li> <li _ngcontent-ng-c3779765592="">Total income for Q4FY26 was Rs. 18,308.20 lakh, reflecting a YoY growth of 13.50% from Rs. 16,130.34 lakh and a QoQ growth of 0.89% from Rs. 18,146.75 lakh in Q3FY26.</li> <li _ngcontent-ng-c3779765592="">Net profit for Q4FY26 reached Rs. 1,163.46 lakh, which is a YoY increase of 0.52% compared to Rs. 1,157.50 lakh in Q4FY25, but a QoQ decline of 59.32% from Rs. 2,860.00 lakh in Q3FY26.</li> <li _ngcontent-ng-c3779765592="">For the full year FY26, revenue from operations reached Rs. 67,102.99 lakh, growing 7.67% YoY from Rs. 62,323.01 lakh in FY25.</li> <li _ngcontent-ng-c3779765592="">Annual total income for FY26 was Rs. 70,448.39 lakh, an increase of 9.10% over Rs. 64,570.72 lakh in FY25.</li> <li _ngcontent-ng-c3779765592="">Annual net profit for FY26 stood at Rs. 8,789.38 lakh, registering a YoY growth of 6.74% from Rs. 8,234.64 lakh in FY25.</li> <li _ngcontent-ng-c3779765592="">Earnings Per Share (EPS) for the full year FY26 was Rs. 43.88, compared to Rs. 41.11 in FY25.</li> </ul> <p><strong _ngcontent-ng-c3779765592="">Business Highlights:</strong></p> <ul> <li _ngcontent-ng-c3779765592=""><strong _ngcontent-ng-c3779765592="">Segment Performance:</strong> The company operates under a single business segment namely 'Pharmaceutical Business'.</li> <li _ngcontent-ng-c3779765592=""><strong _ngcontent-ng-c3779765592="">Dividend:</strong> The Board of Directors has recommended a dividend of 18%, which is Rs. 1.80 per share on the face value of Rs. 10 per share for the year ended March 31, 2026.</li> <li _ngcontent-ng-c3779765592=""><strong _ngcontent-ng-c3779765592="">Growth Targets:</strong> The company is targeting a revenue of Rs. 1,00,000 lakh within the next 3 years. It aims to achieve an annual growth rate of 15-18%, driven by strong performance in the cardiac, diabetic, dermatology, and ENT segments.</li> <li _ngcontent-ng-c3779765592=""><strong _ngcontent-ng-c3779765592="">International Footprint:</strong> The company currently exports to 60+ countries and aims to expand this footprint to 90 countries over the next 2-3 years. It has recently entered the Canadian market and received approvals from TGA - Australia and EU GMP.</li> <li _ngcontent-ng-c3779765592=""><strong _ngcontent-ng-c3779765592="">Product Portfolio:</strong> The company has a robust portfolio of over 1,700 registered products, with an additional 700 products currently in the pipeline.</li> <li _ngcontent-ng-c3779765592=""><strong _ngcontent-ng-c3779765592="">Green Energy:</strong> The company is nearly a 100% green renewable energy consuming organization, supported by new solar plants at its Mehsana and Khatraj factories, alongside existing windmills.</li> <li _ngcontent-ng-c3779765592=""><strong _ngcontent-ng-c3779765592="">Investment Holdings:</strong> As of March 31, 2026, FII holding in the company stood at 5.20% and DII at 1.08%, compared to 5.00% FII holding as of March 31, 2025.</li> </ul> <p _ngcontent-ng-c3779765592=""><strong _ngcontent-ng-c3779765592="">Munjal Patel, Director, Lincoln Pharmaceuticals, said:</strong> "We are pleased to conclude FY26 on a strong note with healthy growth momentum driven by robust demand, improved operational efficiencies and consistent execution across markets. We remain focused on strengthening our product portfolio, expanding our domestic and international presence and investing in research and manufacturing capabilities. Backed by a debt-free balance sheet and strong fundamentals, we remain confident of sustaining profitable growth and creating long-term value for stakeholders."</p> <p><a class="lb" href="/get-document/post/pdf/5665830/" target="_blank">Result PDF</a></p>

• Trendlyne
• 1 month 3 weeks ago